C Difficile Infection

Data from the phase 3 study confirmed the lot consistency, immunogenicity, safety, and tolerability of a toxoid-based Clostridioides difficile vaccine.

Ciprofloxacin, ceftriaxone, and piperacillin/tazobactam showed the greatest associations with adverse drug reaction case reports related to CDI.

Although respondents agreed on the relevance of the gut microbiota in IBD, attitudes toward the clinical application of microbiome-based therapies varied.

A retrospective cohort study of inpatient encounters from 3 hospitals in the Duke University Health System showed greater rates of testing among White patients compared to Black and NWNB patients.

New phase 1b data supports further investigation into Adiso Therapeutic's prospective treatment.

New data presented at ACG 2023 showed an approximate 60% success rate of recurrent C difficile prevention in adults with comorbid conditions including CKD and cardiac disease.

Results showed autologous FMT was safe and well-tolerated but did not affect time to normalized intestinal habits compared to placebo.

Announced by AbbVie on October 15, 2023, positive results revealed 59% of patients treated with risankizumab and 40% of patients treated with ustekinumab achieved clinical remission, respectively.

Use of mirtazapine, nortriptyline, and trazodone among hospitalized patients was associated with a greater risk of CDI.

The approval of oral, once-daily etrasimod 2 mg was based on positive data from the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials.

Age, fecal calprotectin level, toxin B PCR cycle threshold, immunosuppression, sex, and creatinine levels were identified as independent risk factors for developing recurrent CDI.

Social vulnerability index, race, and poverty were associated with increased rates of CDI, calling attention to population-level health disparities.

Results from the systematic review and meta-analysis showed FMT restored the normal microbiome, reduced the risk of gastrointestinal infections, and did not lead to increased adverse events in patients with HIV.

Findings revealed more than 5,000 excess deaths from CDI and 35.6% excess risk compared to the expected number of disease deaths calculated using data from the National Vital Statistics System.

Findings showed colonization with toxigenic C. difficile was associated with a greater risk of CDI during hospitalization than cross-transmission.

Survey results showed patients with a history of live biotherapeutic product therapy preferred rectally administered treatment while patients who had not received live biotherapeutic product therapy would be willing to consider it.

Patients with CDI and COVID-19 faced a higher risk of mortality and had higher CCI scores, a longer length of stay, and greater total hospital costs than patients infected with COVID-19 but not CDI.

Investigators called attention to low patient-reported levels of clinician recommendation for colorectal cancer screening during wellness visits, noting the prevalence was lowest among those without insurance and without a usual source of care.

Patients with CDI treated with oral metronidazole experienced significantly more first-line drug changes compared to those on fidaxomicin, although there were no significant differences observed in the global or clinical cure rate between the two treatments.

Vedolizumab, anti-TNF, and 5-ASA treatments were not linked to an increased risk of CDI, but investigators noted other baseline variables were significantly associated with CDI risk in patients with IBD.

Results from the study found a high risk of CDI associated with clindamycin and low risk associated with doxycycline and minocycline, also highlighting variation in CDI risk within and between classes of antibiotics.

A Mayo Clinic study shows FMT may provide benefit for patients experiencing recurrent infections during their C difficile treatment.

A protein targeted by some marketed lipid-lowering agents may increase risk of developing irritable bowel disease.

The first known dose-effect relationship study between colorectal neoplasia and smoking in patients with IBD strengthens the importance of achieving cessation.

New cohort analysis data provide more context into what factors influence the benefit of FMT in patients with recurrent CDI.

A study from China suggests calcium and magnesium malnutrition is associated with Crohn's disease inflammation and activity.

New data from the CONFIRM trial show the noninvasive FIT testing method is increasing in preference over colonoscopy by about 20% annually.

A cross-sectional analysis from China suggests approximately 1 in 10 individuals suffer from incontinence, though not all are seeking adequate care or specialist consultation.

Early-stage data support KAN-101, a liver-targeting drug that's vying to become the first treatment approved to treat celiac disease.

The reported C difficile healthcare-acquired infections rates per 10,000 patient days did not significantly change. The rates were 8.07 in the 6-month preintervention period and 8.77 in the intervention period for facilities A and B combined.